John J. Trizzino serves as the President and Chief Operating Officer at Novavax, Inc., a biotechnology company focused on developing innovative vaccines. With a robust background in the pharmaceutical industry, Trizzino has been instrumental in steering Novavax through critical phases of growth and development. Prior to his current role, he held the position of Executive Vice President, Chief Business Officer, and Chief Financial Officer at Novavax, showcasing his versatility and deep understanding of both the operational and financial aspects of the business. Trizzino's career in the biopharmaceutical sector spans several decades, during which he has amassed a wealth of experience in corporate strategy, business development, and financial management. Before joining Novavax, he served in various senior executive roles at companies such as Coventry First, LLC, and Genaera Corporation. His strategic vision and leadership have been pivotal in advancing Novavax's vaccine candidates, particularly during the global effort to combat the COVID-19 pandemic. Under his guidance, Novavax has made significant strides in clinical development and manufacturing, positioning the company as a key player in the vaccine market. As President and COO, Trizzino oversees the day-to-day operations and strategic initiatives at Novavax, ensuring the company's continued progress and success. His role involves managing a diverse team of professionals, driving innovation, and maintaining the company's commitment to delivering safe and effective vaccines. Trizzino's leadership is characterized by a collaborative approach and a focus on achieving long-term goals, making him a vital asset to Novavax as it continues to navigate the complex landscape of vaccine development and commercialization.